KPV — Peptide Protocol Wiki reference

Subcutaneous implant increases pain-free sun exposure via melanogenesis.

Consult the detailed side effects profile for full information.

Is KPV FDA approved?

KPV, being only three amino acids in length, is too small to engage melanocortin receptors with meaningful affinity.

This receptor-independent mechanism was confirmed by studies showing that KPV retains anti-inflammatory activity in cells lacking melanocortin receptor expression and in the presence of melanocortin receptor antagonists.

Full-length alpha-MSH exerts anti-inflammatory effects partly through MC1R activation and partly through receptor-independent mechanisms.

KPV Peptide: Anti-Inflammatory Tripeptide Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About KPV 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides KPV Immune Support Healing & Tissue Repair preclinical KPV Also known as: Lys-Pro-Val, Alpha-MSH C-terminal tripeptide, KPV tripeptide Compare with 2 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated January 29, 2026 Citations Verified TL;DR KPV is a naturally occurring anti-inflammatory tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-MSH.

It inhibits NF-kB signaling independently of melanocortin receptors and is transported into intestinal epithelial cells via the PepT1 transporter, making it a promising candidate for inflammatory bowel disease research.

Browse all immune peptides → Table of Contents 📌 TL;DR • Potent anti-inflammatory activity without melanocortin receptor binding • Inhibits NF-kB nuclear translocation • Investigated for inflammatory bowel disease • Crosses cell membranes and enters the nucleus Community-Reported Side Effects Anecdotal ?

nflammatory effects for gut health (IBD/colitis) and immune modulation 💉 Dosing Amount 200-500 mcg per injection (SC); or oral capsules as directed Frequency Once daily (SC); 1-2 times daily (oral) Duration 4-8 weeks, or longer for chronic conditions 💊 Administration Route SC Schedule Once daily (SC); 1-2 times daily (oral) Timing No specific timing requirement; oral doses on empty stomach may improve absorption 📅 Cycle Duration 4-8 weeks, or longer for chronic conditions Repeatable Yes Preparation & Storage Diluent: Bacteriostatic water ⚗️ Suggested Bloodwork ( 6 tests) CRP and ESR When: Baseline Why: Baseline inflammatory markers CBC with differential When: Baseline Why: Baseline immune cell counts CMP with liver enzymes When: Baseline Why: Baseline metabolic function Fecal calprotectin (if IBD) When: Baseline Why: Baseline intestinal inflammation marker CRP When: 4 weeks Why: Monitor inflammatory marker response Fecal calprotectin (if IBD) When: 4-6 weeks Why: Assess gut inflammation improvement 💡 Key Considerations → Its small size makes it a PepT1 transporter substrate, allowing direct intestinal epithelial uptake when taken orally → Contraindication: No formal contraindications established; use cautiously in immunocompromised patients Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Restore access No thanks, continue reading Related Reading Peptide BPC-157 body protection compound peptide Peptide Thymosin Alpha-1 immune modulating peptide Peptide Glutathione peptide How KPV works at the cellular level Overview of KPV benefits and applications Scientific Details Molecular Formula C16H30N4O4 Molecular Weight 342.4 Da CAS Number 67727-97-3 Sequence Lys-Pro-Val What is KPV?

While alpha-MSH is well known for its role in melanogenesis and appetite regulation through melanocortin receptors (particularly MC1R and MC4R), research beginning in the 1980s and 1990s demonstrated that the C-terminal tripeptide fragment KPV retains significant anti-inflammatory activity despite being too small to bind to melanocortin receptors.

The anti-inflammatory properties of alpha-MSH were first recognized in classical antipyretic assays, where the peptide reduced fever induced by interleukin-1 and other pyrogens.

This finding was surprising because it demonstrated that anti-inflammatory signaling by alpha-MSH fragments could occur through a mechanism entirely independent of the melanocortin receptor system.

Its small size, oral bioavailability potential, and favorable safety profile in preclinical models make it an attractive candidate for further development.

Mechanism of Action # NF-kB Inhibition # The central anti-inflammatory mechanism of KPV involves inhibition of the nuclear factor kappa-B (NF-kB) signaling pathway, the master transcriptional regulator of inflammatory gene expression.

Upon stimulation by pro-inflammatory signals (such as TNF-alpha, IL-1beta, or lipopolysaccharide), the IkB kinase (IKK) complex phosphorylates IkB-alpha, targeting it for ubiquitin-mediated proteasomal degradation.

The downstream consequence is reduced expression of pro-inflammatory cytokines including TNF-alpha, IL-6, IL-8, and IL-1beta, as well as reduced expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).

Covers redox cycling, detoxification, immune support, IV vs oral bioavailability, and dosing.

Melanocortin Receptor-Independent Activity # A critical distinguishing feature of KPV is that its anti-inflammatory activity does not require melanocortin receptor binding.

The receptor-independent mechanism involves direct intracellular action.

thin the cell, where it can directly interact with components of the NF-kB signaling pathway.

This intracellular mode of action distinguishes KPV from most peptide therapeutics, which typically act at cell surface receptors.

PepT1 is a proton-coupled oligopeptide transporter expressed on the apical membrane of intestinal epithelial cells that is responsible for the absorption of dietary di- and tripeptides from the intestinal lumen.

Importantly, PepT1 expression is upregulated in the inflamed intestinal epithelium of patients with IBD, potentially creating a natural targeting mechanism whereby more KPV is absorbed at sites of intestinal inflammation.

Once inside epithelial cells, KPV can exert its anti-inflammatory effects by inhibiting NF-kB and reducing production of inflammatory mediators.

This PepT1-mediated uptake mechanism provides a rationale for oral administration of KPV for intestinal inflammatory conditions, as the peptide can b

Preclinical Evidence # Colitis Models # The most developed preclinical evidence for KPV pertains to its efficacy in experimental models of inflammatory bowel disease.

In the dextran sodium sulfate (DSS) model of colitis, which mimics features of ulcerative colitis, oral administration of KPV significantly reduced disease activity index scores, colonic weight-to-length ratio (a measure of edema and inflammation), and histological damage scores.

These benefits were associated with reduced tissue levels of TNF-alpha, IL-6, and other pro-inflammatory cytokines, as well as reduced neutrophil infiltration as measured by myeloperoxidase activity.

In the trinitrobenzene sulfonic acid (TNBS) model, which generates a Th1-dominant inflammatory response more similar to Crohn's disease, KPV similarly demonstrated protective effects, reducing mucosal damage, inflammatory cell infiltration, and pro-inflammatory cytokine production.

this formulation improved colonic delivery and enhanced therapeutic efficacy in the DSS colitis model compared to free KPV.

Hyaluronic acid-functionalized nanoparticles have also been investigated, exploiting the overexpression of CD44 receptors on inflamed colonic epithelium to achieve targeted delivery.

Wound Healing and Dermatology # KPV has been investigated for anti-inflammatory effects in dermatological contexts, consistent with the known expression and function of alpha-MSH in the skin.

In preclinical models of cutaneous inflammation, KPV reduced inflammatory cell infiltration, edema, and expression of inflammatory mediators.

In wound healing models, KPV treatment has been associated with reduced inflammatory phase duration and accelerated transition to the proliferative phase, resulting in faster wound closure.

resent potential target conditions, based on efficacy in DSS and TNBS models respectively.

The distinct mechanism of action (direct NF-kB inhibition without immunosuppression) may provide additive or synergistic benefits when combined with existing treatments.

The translation of preclinical efficacy in rodent colitis models to human IBD is historically challenging, as many agents showing strong precl